Pendaftaran Diakses untuk Eligitabilitas (N=223)

Eklusi (N = 63)
Tidak termasuk kriteria inklusi (N=44)
Menolak untuk partisipasi (N=19)

Random (N =160)
40 PPG, 40 PPB, 40 PG, 40 PB

Alokasi

Intervensi Metformin (N=80) Intervensi Plasebo (N=80)

Keluar (N = 12) Keluar (N = 8)

Menolak melanjutkan (N=8) Menolak melanjutkan (N=6)
Kehilangan Kontak (N=3) Kehilangan Kontak (N=2)
Alasan Lain (N=1) 4 PPG, 2 PPB, 2 PG, 0 PB
3 PPG, 4 PPB, 3 PG, 2 PB

Analisa (N=68) Analisa (N=72)

Akhir Percobaan (N=140)

 Prepubertal (Tanner Stage I) Pubertal (Tanner Stages II–V)
Placebo Metformin Placebo Metformin
Variable
Baseline 6 mo Baseline 6 mo Pa Baseline 6 mo Baseline 6 mo Pa
(n = 40) (n = 34) (n = 40) (n = 33) (n = 40) (n = 38) (n = 40) (n = 35)
Adherence, % 86 ± 3 94 ± 2 87 ± 3 91 ± 2
Height, cm . .56
141.3 ± 144.6 ± 140.6 ± 144.0 ± 160.5 ± . 162.9 ± 159.0 ± 161.5 ±
8
1.5 1.5 1.6 1.5 1.4 1.3 1.4 1.4
8
Weight, kg . .56
59.9 ± 60.2 ± 55.8 ± 54.0 ± 80.5 ± 81.7 ± 76.9 ± 77.4 ±
1
2.0 2.2 2.1 2.2 2.4 2.4 2.4 2.5
3
BMI . .22b
29.2 ± 28.2 ± 28.2 ± 26.5 ± 30.6 ± 30.2 ± 29.4 ± 28.5 ±
1
0.6 0.6 0.6 0.7 0.5 0.5 0.5 0.6
9
BMI z score . .1
4.0 ± 0.2 4 ± 0.2
4 ± 0.2 3 6 ± 0.2 0 3.2 ± 0.2 3.0 ± 0.2 3.2 ± 0.2 2.8 ± 0.2
3. 2.
4
Waist perimeter, . .89b
94.5 ± 94.6 ± 89.3 ± 88.7 ± 95.4 ± 94.6 ± 93.7 ± 92.9 ±
cm 7
1.9 1.9 2.0 2.0 1.8 1.9 1.8 1.9
2
Fat mass, % . .77
38 ± 0.8 37 ± 1.0 37 ± 0.8 35 ± 1.0 4 37 ± 0.8 37 ± 1.0 38 ± 0.9 37 ± 1.0
1
Fasting glucose, 87.1 ± 84.6 ± 85.6 ± 82.9 ± . 86.7 ± 86.1 ± 87.7 ± 86.4 ± .63
mg/dL 1.4 1.7 1.4 1.7 8 1.0 1.2 1.1 1.3
8
Fasting insulin, 12.2 ± 12.0 ± 12.9 ± 13.4 ± . 20.8 ± 21.6 ± 20.0 ± 20.1 ± .79
µu/mL 1.3 1.4 1.4 1.5 6 1.8 1.6 1.9 1.8
9
HOMA-IR 2.6 ± 0.3 2.5 ± 0.3 2.7 ± 0.3 2.8 ± 0.3 . 4.5 ± 0.4 4.7 ± 0.4 4.4 ± 0.4 4.4 ± 0.4 .73
7
2
Quicki 0.339 ± 0.332 ± 0.328 ± 0.338 ± . 0.311 ± 0.310 0.311 ± 0.314 ± .60
0.005 0.004 0.005 0.005 0 0.004 ±0.004 0.004 0.004
1
TG, mg/dL 68.2 ± 62.9 ± 65.1± 58.8 ± . 74.7 ± 73.6 ± 69.1 ± 64.0 ± .90
3.8 3.5 3.9 3.5 9 1.8 4.1 5.8 4.6
2
TC, mg/dL 162.0 ± 157.5 ± 160.9 ± 155.3 ± . 158.8 ± 152.6 ± 155.1 ± 155.1 ± .17
4.8 4.0 4.9 4.2 7 4.4 4.2 4.6 4.4
9
HDL-C, mg/dL 46.2 ± 49.6 ± 43.7 ± 48.7 ± . 47.8 ± 47.7 ± 46.9 ± 50.3 ± .09
1.5 1.8 1.6 1.9 2 1.8 2.1 1.9 2.1
2
LDL-C, mg/dL 99.3 ± 94.3 ± 99.5 ± 93.6 ± . 94.9 ± 89.1 ± 90.0 ± 86.4 ± .55
4.7 4.3 4.9 4.4 8 3.7 3.6 3.8 3.8
3
VLDL-C, mg/dL 13.8 ± 13.0 ± 12.7 ± 11.0 ± . 14.6 ± 12.2 ± 11.7 ± 11.3 ± .06
0.7 0.6 0.8 0.6 4 1.2 1.0 1.2 1.0
0
Apo A1, mg/dL 130.1 ± 135.0 ± 127.8 ± 136.2 ± . 130.7 ± 134.2 ± 135.0 ± 142.4 ± .33
3.8 4.2 3.9 4.2 4 3.6 3.9 3.8 4.1
4
Apo B, mg/dL 70.3 ± 70.0 ± 66.1 ± 69.7 ± . 74.3 ± 72.1 ± 83.4 ± 85.0 ± .55
2.9 3.0 2.9 3.0 2 4.4 6.3 5.0 7.2
8

Prepubertal (Tanner Stage I) Pubertal (Tanner Stages II–V)

Placebo Metformin Placebo Metformin
Variable
Baseline 6 mo Baseline 6 mo Pa Baseline 6 mo Baseline 6 mo Pa
(n = 40) (n = 34) (n = 40) (n = 33) (n = 40) (n = 38) (n = 40) (n = 35)

Adiponectin, .
12.4 ± 13.5 ± 11.8 ± 15.4 ±
mg/L 2 7.9 ± 0.8 7.5 ± 0.8
1.2 1.3 1.2 1.4
3
9.4 ± 0.9 10.3 ± 0.8 .20

Leptin